Low Leverage / Relative Balance Sheet StrengthLow debt relative to equity gives the company structural financial flexibility versus highly levered peers. Over a multi-month horizon this reduces refinancing pressure and preserves options to fund R&D or operations via equity or modest borrowing, improving survival odds while cash burn persists.

Improving Cash Burn In 2024–2025A reduction in cash burn versus prior years signals operational tightening or lower cash intensity. If sustained, this materially extends runway, lowers near-term external funding needs, and makes operational turnaround or pathway-to-revenue scenarios more attainable over the next several months.

Narrowing Losses Year-over-yearProgress toward smaller operating and net losses indicates the business is moving toward cost control or efficiency gains. Continued narrowing improves prospects for reaching break-even or reducing financing frequency, supporting longer-term plan execution and investor receptivity over a 2–6 month horizon.

Bears Say

Zero Recent RevenueA collapse to zero reported revenue is a structural concern: without recurring sales the company lacks core commercial cash inflows, increasing reliance on external funding or one-off proceeds. This weakens prospects for sustainable operations absent new products or partnerships.

Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flows force dependence on external capital (equity or debt), which can dilute existing holders and constrain strategic choices. Over months this raises execution risk if financing windows tighten or capital costs rise.

Eroding Equity And Total AssetsA declining equity base and shrinking assets reduce the company’s financial buffer and borrowing capacity. Continued erosion diminishes flexibility to fund R&D or clinical programs and increases vulnerability to adverse shocks or tougher capital market conditions.

IMMU FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was kr4.17 and its highest was kr10.98 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is kr296.99M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is May 08, 2026 which is in 78 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on Feb 11, 2026. The company reported -kr0.74 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.74.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -kr0.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.055%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in SE:IMMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.